- Q1 2024 Bioatla Inc Earnings Call TranscriptMay 14, 2024$2.61 (-1.14%)Earnings
- Q4 2023 Bioatla Inc Earnings Call TranscriptMar 26, 2024$3.01 (+29.18%)Earnings
- Bioatla Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Bioatla Inc R&D Day TranscriptDec 13, 2023
- Q3 2023 Bioatla Inc Earnings Call TranscriptNov 07, 2023$1.76 (-4.35%)Earnings
- Bioatla Inc at HC Wainwright Investment Conference - New York(Pre Recorded) TranscriptSep 11, 2023
- Bioatla Inc at HC Wainwright Immune Cell Engager Virtual Conference TranscriptAug 17, 2023
- Q2 2023 Bioatla Inc Earnings Call TranscriptAug 01, 2023$2.88 (-3.68%)Earnings
- Bioatla Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Bioatla Inc at JMP Securities Life Sciences Conference TranscriptMay 15, 2023
- Q1 2023 Bioatla Inc Earnings Call TranscriptMay 11, 2023$3.21 (-3.02%)Earnings
- Q4 2022 Bioatla Inc Earnings Call TranscriptMar 23, 2023$2.3 (-1.71%)Earnings
- Q3 2022 Bioatla Inc Earnings Call TranscriptNov 03, 2022$6.36 (-1.40%)Earnings
- Q2 2022 Bioatla Inc Earnings Call TranscriptAug 09, 2022$3.61 (-3.48%)Earnings
- Q1 2022 Bioatla Inc Earnings Call TranscriptMay 04, 2022$4.08 (+6.53%)Earnings
Bioatla Inc at HC Wainwright Immune Cell Engager Virtual Conference Transcript
Greetings. My name is Arthur He, a senior biotech analyst at HC Wainwright. And thanks for joining us to have a conversation with BioAtla's management: Ms. Sheri Lydick, Chief Commercial Officer; Dr. Eric Sievers, Chief Medical Officer; and Dr. William Boyle, Head of Translational Science.
BioAtla is a clinical-stage biopharmaceutical company developing novel therapies for solid tumors based on its proprietary conditionally active biologics platform. The company currently has four drugs in clinical development and multiple preclinical candidates across different modalities. Today's conversation will be focused on their bispecific T-cell engagers.
To discuss the company's CAB technology and its development strategy in T-cell engagers, I welcome Sheri, Eric, and Bill to this fireside chat. Good day, Sheri, Eric, and Bill.
Welcome. Thank you.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)